Slideshow
Author(s):
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
NeurologyLive® Friday 5 — April 18, 2025
Episode 139: Sleep and Seizures: Emerging Insights From AAN 2025
Migraine Treatment Zavegepant Shows No Meaningful Impact on Oral Contraceptive Exposure
Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care
Large Danish Cohort Study Reveals No Significant Association Between HLA Alleles and Migraine
Afterimage Duration Significantly Longer in Migraine With Aura Than Without